Fugitive Ronald Fisher, using the alias Richard Graydon, secured high-level biotech roles, including interim Chief Medical Officer. His success stemmed from a systemic failure in due diligence, as multiple companies and recruiters never verified his fabricated academic degrees (Stanford, Harvard) or his non-existent medical license, exposing a critical vulnerability in industry hiring practices.
An FDA panel voted against Capricor Therapeutics' Duchenne drug, primarily because the company altered its statistical analysis plan after the study was complete but before unblinding. The FDA viewed this as a potential manipulation to achieve a more favorable outcome, critically undermining the credibility of the efficacy data presented.
The FDA panel's stringent data requirements for Capricor's Duchenne drug for older boys highlights a perceived regulatory inconsistency. This tough stance contrasts with previous accelerated approvals for Sarepta's Duchenne therapies, which were granted despite unproven efficacy. This raises questions about whether the agency applies different standards to similar patient populations over time.
In response to emotional patient testimony supporting Capricor's Duchenne drug, an FDA official reframed regulatory strictness as a crucial patient safeguard. The argument is that high standards and rejecting drugs with weak data are essential to protect patients from the risks and false hope of ineffective treatments, turning a perceived barrier into a protective measure.
While former FDA official Vinay Prasad was known for his stringent reviews, the continued institutional skepticism towards Capricor's drug after his departure suggests the concerns were widespread among FDA staff. This indicates that attributing the FDA's recent restrictive stance solely to one individual's leadership style is an oversimplification of the agency's internal consensus on data quality.
Under new CEO Luke Meals, GSK is implementing a strategy of fiscal tightening combined with aggressive pipeline investment. The company plans to cut $2.5 billion in costs while doubling its planned Phase 3 trial starts from 10 to 20 this year. This approach aims to fuel long-term growth and meet a $53.2B sales target by 2031 while navigating a major patent cliff.